Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of itopride HCl in functional dyspepsia
2004-004308-19Phase 3Terminated
- Sponsor
- Axcan Pharma Inc.
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of itopride in functional dyspepsia (FD), sponsored by Axcan Pharma Inc. Primary endpoints: Long-term safety of itopride and Long-term therapeutic benefit. Started May 2005; status: terminated.
02
Drugs
itopride
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on 2004-004308-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004308-19.